Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Burotam vs Brosym (Cefoperazone/Sulbactam) in Healthy Volunteers
NCT05654090Phase 4Unknown
- Sponsor
- Yung Shin Pharmaceutical Industry
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Burotam in bacterial infection, sponsored by Yung Shin Pharmaceutical Industry. Status: unknown.
02
Drugs
Burotam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT05654090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05654090.